Major Depressive Disorder
SPTXSeaport TherapeuticsCatalyst overview
Research summary
This catalyst tracks a Phase 2b data readout for GlyphAllo/Glyph Allopregnanolone (SPT-300) (Neuroactive Steroid) in Major Depressive Disorder. The expected timing is based on the latest available company guidance and may change.
06/08/26:- BUOY-1 enrollment is on track; Ph2b topline data expected H1 2027. 08/03/26:- BUOY-1 enrollment is on track. Topline data expected H1 2027.
Verification
Confirm timing and program details against the company announcement or filing.